Breast cancer prognosis is better in patients who develop subsequent metachronous thyroid cancer
Breast cancer (BC) and thyroid cancer (TC) are common malignancies among females. However, the connection between TC and BC is not well understood. To explore the relationship between these two cancers and to determine the effect of second metachronous TC on BC survival, we compared BC patients with...
Gespeichert in:
| Veröffentlicht in: | PloS one 2019-05, Vol.14 (5), p.e0215948-e0215948 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0215948 |
|---|---|
| container_issue | 5 |
| container_start_page | e0215948 |
| container_title | PloS one |
| container_volume | 14 |
| creator | Lei, Kefeng He, Xujun Yu, Leibo Ni, Chao Chen, Hailong Guan, Dandan Sun, Kewang Zou, Hai |
| description | Breast cancer (BC) and thyroid cancer (TC) are common malignancies among females. However, the connection between TC and BC is not well understood. To explore the relationship between these two cancers and to determine the effect of second metachronous TC on BC survival, we compared BC patients with or without second primary TC using data from the Surveillance, Epidemiology, and End Results (SEER) database. We extracted data from patients with only BC or TC and from BC patients with a second metachronous cancer from 2000-2014. Differences in the clinicopathological and treatment characteristics between BC patients with or without second metachronous TC were analyzed by chi-square tests. Multivariate analyses of BC survival were performed by using Cox regression models. Comparison of disease-specific survival (DSS) curves between these cohorts was performed with the log-rank (Mantel-Cox) test. Survival analyses were also performed using data from 1980-1994. Within this dataset, we found 1,262 BC cases in which a second metachronous TC (BC2TC) developed, accounting for 3.1% of all metachronous cancers following BC from 2000-2014. No significant differences were found in molecular markers. In addition, the mean age at BC diagnosis was younger in the BC2TC group than in the BC group (55.418 y vs 60.273 y). Half of the BC2TC patients developed TC in the first three years following BC diagnosis. Patients with BC2TC showed better DSS than those with BC alone from 2000-2014 (P |
| doi_str_mv | 10.1371/journal.pone.0215948 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2219590777</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A584150144</galeid><doaj_id>oai_doaj_org_article_c37d945b105b4218b0c7235f8e2362ad</doaj_id><sourcerecordid>A584150144</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-6135b710df39ce0b461da0dba8f17a84f9e46719fe9259981efc7875b6d2e7933</originalsourceid><addsrcrecordid>eNqNk12L1DAUhoso7rr6D0QLgujFjPlOcyOsix8DCwt-3cY0PZ3J0mlqkq7uvzfjdJep7IU00HDynPckb3KK4ilGS0wlfnPpx9Cbbjn4HpaIYK5Yda84xoqShSCI3j-YHxWPYrxEiNNKiIfFEcWIESnkcfHjXQATU2lNbyGUQ_Dr3kcXyzxqSCnHXF8OJjnoUyx_bXzZwBV0fijjWEf4OeZ4uYVk7Cb43o-xTJvr4F0zST4uHrSmi_Bk-p8U3z68_3r2aXF-8XF1dnq-sEKRtBCY8lpi1LRUWUA1E7gxqKlN1WJpKtYqYEJi1YIiXKkKQ2tlJXktGgJSUXpSPN_rDp2PejInakKw4gpJKTOx2hONN5d6CG5rwrX2xum_AR_W2oTkbAfaUtkoxmuMeM0IrmpkJaG8rYBQQUyTtd5O1cZ6C43NJgTTzUTnK73b6LW_0oIpKjnLAq8mgeCzhzHprYsWus70kE3c7btSSnEuMvriH_Tu003U2uQDuL71ua7diepTXjHMEWa7sss7qPw1sHU2v6TW5fgs4fUsITMJfqe1GWPUqy-f_5-9-D5nXx6wGzBd2kTfjcn5Ps5Btgdt8DEGaG9NxkjvGuHGDb1rBD01Qk57dnhBt0k3L5_-AexPA3w</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2219590777</pqid></control><display><type>article</type><title>Breast cancer prognosis is better in patients who develop subsequent metachronous thyroid cancer</title><source>MEDLINE</source><source>TestCollectionTL3OpenAccess</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Lei, Kefeng ; He, Xujun ; Yu, Leibo ; Ni, Chao ; Chen, Hailong ; Guan, Dandan ; Sun, Kewang ; Zou, Hai</creator><contributor>Alzahrani, Ali S.</contributor><creatorcontrib>Lei, Kefeng ; He, Xujun ; Yu, Leibo ; Ni, Chao ; Chen, Hailong ; Guan, Dandan ; Sun, Kewang ; Zou, Hai ; Alzahrani, Ali S.</creatorcontrib><description>Breast cancer (BC) and thyroid cancer (TC) are common malignancies among females. However, the connection between TC and BC is not well understood. To explore the relationship between these two cancers and to determine the effect of second metachronous TC on BC survival, we compared BC patients with or without second primary TC using data from the Surveillance, Epidemiology, and End Results (SEER) database. We extracted data from patients with only BC or TC and from BC patients with a second metachronous cancer from 2000-2014. Differences in the clinicopathological and treatment characteristics between BC patients with or without second metachronous TC were analyzed by chi-square tests. Multivariate analyses of BC survival were performed by using Cox regression models. Comparison of disease-specific survival (DSS) curves between these cohorts was performed with the log-rank (Mantel-Cox) test. Survival analyses were also performed using data from 1980-1994. Within this dataset, we found 1,262 BC cases in which a second metachronous TC (BC2TC) developed, accounting for 3.1% of all metachronous cancers following BC from 2000-2014. No significant differences were found in molecular markers. In addition, the mean age at BC diagnosis was younger in the BC2TC group than in the BC group (55.418 y vs 60.273 y). Half of the BC2TC patients developed TC in the first three years following BC diagnosis. Patients with BC2TC showed better DSS than those with BC alone from 2000-2014 (P<0.001). However, this superiority was not significant from 1980-1994 (P = 0.579) or for TNM stage I BC (P = 0.927) and grade I BC (P = 0.431) from 2000-2014. In conclusion, the incidence of BC2TC has increased dramatically during the past 15 years. In addition, patients with BC2TC showed better DSS than patients with BC alone, especially in cases from 2000-2014.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0215948</identifier><identifier>PMID: 31042767</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Analysis ; Biology and Life Sciences ; Breast cancer ; Breast Neoplasms - complications ; Breast Neoplasms - diagnosis ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Cancer ; Cancer patients ; Cancer therapies ; Chemotherapy ; Databases, Factual ; Diagnosis ; Epidemiology ; Female ; Females ; Health aspects ; Health care access ; Hospitals ; Humans ; Intelligence gathering ; Medical diagnosis ; Medical prognosis ; Medicine and Health Sciences ; Middle Aged ; Mortality ; Neoplasm Grading ; Neoplasm Staging ; Neoplasms, Second Primary - complications ; Neoplasms, Second Primary - diagnosis ; Patients ; Prognosis ; Proportional Hazards Models ; Radiation therapy ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Regression analysis ; Regression models ; Sentinel surveillance ; Surgery ; Surveillance ; Survival ; Survival Analysis ; Thyroid ; Thyroid cancer ; Thyroid diseases ; Thyroid Neoplasms - complications ; Thyroid Neoplasms - diagnosis ; Thyroid Neoplasms - pathology ; Tumors ; Womens health</subject><ispartof>PloS one, 2019-05, Vol.14 (5), p.e0215948-e0215948</ispartof><rights>COPYRIGHT 2019 Public Library of Science</rights><rights>2019 Lei et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 Lei et al 2019 Lei et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-6135b710df39ce0b461da0dba8f17a84f9e46719fe9259981efc7875b6d2e7933</citedby><cites>FETCH-LOGICAL-c692t-6135b710df39ce0b461da0dba8f17a84f9e46719fe9259981efc7875b6d2e7933</cites><orcidid>0000-0002-4259-1510</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493754/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493754/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23847,27903,27904,53769,53771,79346,79347</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31042767$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Alzahrani, Ali S.</contributor><creatorcontrib>Lei, Kefeng</creatorcontrib><creatorcontrib>He, Xujun</creatorcontrib><creatorcontrib>Yu, Leibo</creatorcontrib><creatorcontrib>Ni, Chao</creatorcontrib><creatorcontrib>Chen, Hailong</creatorcontrib><creatorcontrib>Guan, Dandan</creatorcontrib><creatorcontrib>Sun, Kewang</creatorcontrib><creatorcontrib>Zou, Hai</creatorcontrib><title>Breast cancer prognosis is better in patients who develop subsequent metachronous thyroid cancer</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Breast cancer (BC) and thyroid cancer (TC) are common malignancies among females. However, the connection between TC and BC is not well understood. To explore the relationship between these two cancers and to determine the effect of second metachronous TC on BC survival, we compared BC patients with or without second primary TC using data from the Surveillance, Epidemiology, and End Results (SEER) database. We extracted data from patients with only BC or TC and from BC patients with a second metachronous cancer from 2000-2014. Differences in the clinicopathological and treatment characteristics between BC patients with or without second metachronous TC were analyzed by chi-square tests. Multivariate analyses of BC survival were performed by using Cox regression models. Comparison of disease-specific survival (DSS) curves between these cohorts was performed with the log-rank (Mantel-Cox) test. Survival analyses were also performed using data from 1980-1994. Within this dataset, we found 1,262 BC cases in which a second metachronous TC (BC2TC) developed, accounting for 3.1% of all metachronous cancers following BC from 2000-2014. No significant differences were found in molecular markers. In addition, the mean age at BC diagnosis was younger in the BC2TC group than in the BC group (55.418 y vs 60.273 y). Half of the BC2TC patients developed TC in the first three years following BC diagnosis. Patients with BC2TC showed better DSS than those with BC alone from 2000-2014 (P<0.001). However, this superiority was not significant from 1980-1994 (P = 0.579) or for TNM stage I BC (P = 0.927) and grade I BC (P = 0.431) from 2000-2014. In conclusion, the incidence of BC2TC has increased dramatically during the past 15 years. In addition, patients with BC2TC showed better DSS than patients with BC alone, especially in cases from 2000-2014.</description><subject>Adult</subject><subject>Analysis</subject><subject>Biology and Life Sciences</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - complications</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Databases, Factual</subject><subject>Diagnosis</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Females</subject><subject>Health aspects</subject><subject>Health care access</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Intelligence gathering</subject><subject>Medical diagnosis</subject><subject>Medical prognosis</subject><subject>Medicine and Health Sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Staging</subject><subject>Neoplasms, Second Primary - complications</subject><subject>Neoplasms, Second Primary - diagnosis</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Radiation therapy</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Regression analysis</subject><subject>Regression models</subject><subject>Sentinel surveillance</subject><subject>Surgery</subject><subject>Surveillance</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Thyroid</subject><subject>Thyroid cancer</subject><subject>Thyroid diseases</subject><subject>Thyroid Neoplasms - complications</subject><subject>Thyroid Neoplasms - diagnosis</subject><subject>Thyroid Neoplasms - pathology</subject><subject>Tumors</subject><subject>Womens health</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk12L1DAUhoso7rr6D0QLgujFjPlOcyOsix8DCwt-3cY0PZ3J0mlqkq7uvzfjdJep7IU00HDynPckb3KK4ilGS0wlfnPpx9Cbbjn4HpaIYK5Yda84xoqShSCI3j-YHxWPYrxEiNNKiIfFEcWIESnkcfHjXQATU2lNbyGUQ_Dr3kcXyzxqSCnHXF8OJjnoUyx_bXzZwBV0fijjWEf4OeZ4uYVk7Cb43o-xTJvr4F0zST4uHrSmi_Bk-p8U3z68_3r2aXF-8XF1dnq-sEKRtBCY8lpi1LRUWUA1E7gxqKlN1WJpKtYqYEJi1YIiXKkKQ2tlJXktGgJSUXpSPN_rDp2PejInakKw4gpJKTOx2hONN5d6CG5rwrX2xum_AR_W2oTkbAfaUtkoxmuMeM0IrmpkJaG8rYBQQUyTtd5O1cZ6C43NJgTTzUTnK73b6LW_0oIpKjnLAq8mgeCzhzHprYsWus70kE3c7btSSnEuMvriH_Tu003U2uQDuL71ua7diepTXjHMEWa7sss7qPw1sHU2v6TW5fgs4fUsITMJfqe1GWPUqy-f_5-9-D5nXx6wGzBd2kTfjcn5Ps5Btgdt8DEGaG9NxkjvGuHGDb1rBD01Qk57dnhBt0k3L5_-AexPA3w</recordid><startdate>20190501</startdate><enddate>20190501</enddate><creator>Lei, Kefeng</creator><creator>He, Xujun</creator><creator>Yu, Leibo</creator><creator>Ni, Chao</creator><creator>Chen, Hailong</creator><creator>Guan, Dandan</creator><creator>Sun, Kewang</creator><creator>Zou, Hai</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-4259-1510</orcidid></search><sort><creationdate>20190501</creationdate><title>Breast cancer prognosis is better in patients who develop subsequent metachronous thyroid cancer</title><author>Lei, Kefeng ; He, Xujun ; Yu, Leibo ; Ni, Chao ; Chen, Hailong ; Guan, Dandan ; Sun, Kewang ; Zou, Hai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-6135b710df39ce0b461da0dba8f17a84f9e46719fe9259981efc7875b6d2e7933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Analysis</topic><topic>Biology and Life Sciences</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - complications</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Databases, Factual</topic><topic>Diagnosis</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Females</topic><topic>Health aspects</topic><topic>Health care access</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Intelligence gathering</topic><topic>Medical diagnosis</topic><topic>Medical prognosis</topic><topic>Medicine and Health Sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Staging</topic><topic>Neoplasms, Second Primary - complications</topic><topic>Neoplasms, Second Primary - diagnosis</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Radiation therapy</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Regression analysis</topic><topic>Regression models</topic><topic>Sentinel surveillance</topic><topic>Surgery</topic><topic>Surveillance</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Thyroid</topic><topic>Thyroid cancer</topic><topic>Thyroid diseases</topic><topic>Thyroid Neoplasms - complications</topic><topic>Thyroid Neoplasms - diagnosis</topic><topic>Thyroid Neoplasms - pathology</topic><topic>Tumors</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lei, Kefeng</creatorcontrib><creatorcontrib>He, Xujun</creatorcontrib><creatorcontrib>Yu, Leibo</creatorcontrib><creatorcontrib>Ni, Chao</creatorcontrib><creatorcontrib>Chen, Hailong</creatorcontrib><creatorcontrib>Guan, Dandan</creatorcontrib><creatorcontrib>Sun, Kewang</creatorcontrib><creatorcontrib>Zou, Hai</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>TestCollectionTL3OpenAccess</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lei, Kefeng</au><au>He, Xujun</au><au>Yu, Leibo</au><au>Ni, Chao</au><au>Chen, Hailong</au><au>Guan, Dandan</au><au>Sun, Kewang</au><au>Zou, Hai</au><au>Alzahrani, Ali S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Breast cancer prognosis is better in patients who develop subsequent metachronous thyroid cancer</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2019-05-01</date><risdate>2019</risdate><volume>14</volume><issue>5</issue><spage>e0215948</spage><epage>e0215948</epage><pages>e0215948-e0215948</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Breast cancer (BC) and thyroid cancer (TC) are common malignancies among females. However, the connection between TC and BC is not well understood. To explore the relationship between these two cancers and to determine the effect of second metachronous TC on BC survival, we compared BC patients with or without second primary TC using data from the Surveillance, Epidemiology, and End Results (SEER) database. We extracted data from patients with only BC or TC and from BC patients with a second metachronous cancer from 2000-2014. Differences in the clinicopathological and treatment characteristics between BC patients with or without second metachronous TC were analyzed by chi-square tests. Multivariate analyses of BC survival were performed by using Cox regression models. Comparison of disease-specific survival (DSS) curves between these cohorts was performed with the log-rank (Mantel-Cox) test. Survival analyses were also performed using data from 1980-1994. Within this dataset, we found 1,262 BC cases in which a second metachronous TC (BC2TC) developed, accounting for 3.1% of all metachronous cancers following BC from 2000-2014. No significant differences were found in molecular markers. In addition, the mean age at BC diagnosis was younger in the BC2TC group than in the BC group (55.418 y vs 60.273 y). Half of the BC2TC patients developed TC in the first three years following BC diagnosis. Patients with BC2TC showed better DSS than those with BC alone from 2000-2014 (P<0.001). However, this superiority was not significant from 1980-1994 (P = 0.579) or for TNM stage I BC (P = 0.927) and grade I BC (P = 0.431) from 2000-2014. In conclusion, the incidence of BC2TC has increased dramatically during the past 15 years. In addition, patients with BC2TC showed better DSS than patients with BC alone, especially in cases from 2000-2014.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>31042767</pmid><doi>10.1371/journal.pone.0215948</doi><tpages>e0215948</tpages><orcidid>https://orcid.org/0000-0002-4259-1510</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2019-05, Vol.14 (5), p.e0215948-e0215948 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2219590777 |
| source | MEDLINE; TestCollectionTL3OpenAccess; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Adult Analysis Biology and Life Sciences Breast cancer Breast Neoplasms - complications Breast Neoplasms - diagnosis Breast Neoplasms - mortality Breast Neoplasms - pathology Cancer Cancer patients Cancer therapies Chemotherapy Databases, Factual Diagnosis Epidemiology Female Females Health aspects Health care access Hospitals Humans Intelligence gathering Medical diagnosis Medical prognosis Medicine and Health Sciences Middle Aged Mortality Neoplasm Grading Neoplasm Staging Neoplasms, Second Primary - complications Neoplasms, Second Primary - diagnosis Patients Prognosis Proportional Hazards Models Radiation therapy Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Regression analysis Regression models Sentinel surveillance Surgery Surveillance Survival Survival Analysis Thyroid Thyroid cancer Thyroid diseases Thyroid Neoplasms - complications Thyroid Neoplasms - diagnosis Thyroid Neoplasms - pathology Tumors Womens health |
| title | Breast cancer prognosis is better in patients who develop subsequent metachronous thyroid cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T12%3A35%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Breast%20cancer%20prognosis%20is%20better%20in%20patients%20who%20develop%20subsequent%20metachronous%20thyroid%20cancer&rft.jtitle=PloS%20one&rft.au=Lei,%20Kefeng&rft.date=2019-05-01&rft.volume=14&rft.issue=5&rft.spage=e0215948&rft.epage=e0215948&rft.pages=e0215948-e0215948&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0215948&rft_dat=%3Cgale_plos_%3EA584150144%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2219590777&rft_id=info:pmid/31042767&rft_galeid=A584150144&rft_doaj_id=oai_doaj_org_article_c37d945b105b4218b0c7235f8e2362ad&rfr_iscdi=true |